<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540812</url>
  </required_header>
  <id_info>
    <org_study_id>LAL-AR/2011</org_study_id>
    <nct_id>NCT01540812</nct_id>
  </id_info>
  <brief_title>Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial protocol intended the optimization of induction treatment with:

        1. Inclusion of PEG-ASP in induction and in the three blocks of consolidation.

        2. Reduction of the dose of daunorubicin, and recent studies have shown that the use of
           high doses of anthracyclines has not brought higher response rates or longer duration

        3. Replacing the poor cytological response at day 14 by the level of ER at the end of
           induction as a criterion to decide the further treatment (consolidation or second
           induction), so as to have only one criterion (the ER) throughout the study to decision
           making.

      For another hand, reducing non-essential drugs consolidation blocks to try to reduce toxicity
      during it, and replace the ASP E. coli in induction and consolidation of PEG-ASP to ensure a
      more sustained asparagine depletion. Also, increasing the dose of methotrexate (3 to 5 g/m2)
      in patients with ALL-T, since there is recent evidence of a higher response rate with this
      strategy.

      Performing an allo-HSCT early (after one cycle of consolidation) for patients with inadequate
      level of ER after two cycles of induction or in those patients who required two courses of
      induction and have obtained proper ER after the second.

      Conducting studies of RD centrally by cytofluorometry following Euroflow consensus standards,
      to avoid bias in making treatment decisions
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Improve the results of the protocol ALL-AR-03 with modifications in the study methodology of residual disease: centralized, Biomed protocols and the cut-off - &lt;0.01% - internationally accepted and changes in the induction and consolidation treatment, without altering the overall design</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate CR rate with addition of PEG-ASP in the induction phase</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standarization of minimal residual disease</measure>
    <time_frame>2 years</time_frame>
    <description>Determination of minimal residual disease in a central laboratory trying to homogenice the results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the toxic mortality</measure>
    <time_frame>2 years</time_frame>
    <description>To assess whether the reduction of daunorubicin in induction and changes in the consolidation drugs reduce toxic mortality in patients in complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the proportion of non-responders or slow responders</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
    <description>Vincristine in induction:5 mg/m2 i.v. days 1, 8, 15 and 22 in induction phase Daunorubicin in induction 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone in induction: 60 mg/m2/ day, i.v. o p.o., days 1 to 14; 30 mg/m2/day, i.v. o p.o., days 15 to 21; 15 mg/m2/day i.v. o p.o., days 21 to 28 Metotrexato 12 mg days 1 and 22 (intrathecal) Cytarabine (ARA-C): 30 mg days 1 and 22 (intrathecal) Hydrocortisone: 20 mg days 1 and 22 (intrathecal) Idarubicin-induction 2 12 mg/m2, i.v., days 1, 3 and 5 Fludarabine in induction-2: Fludarabine 30 mg/m2, i.v., days, 1 to 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine in induction</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin in induction</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone in induction</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metotrexato in induction</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine in induction</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone in induction</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin in induction-2</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine in induction-2</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C in induction-2</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF in induction-2</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone in consolidation-1</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristrine in consolidation-1</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metotrexato in consolidation-1</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-ASP in consolidation-1</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone in consolidation-2</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARA-C in consolidation-2</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-ASP in consolidation-2</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone in consolidation-3</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine in consolidation-3</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metotrexato in consolidation-3</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-ASP in consolidation-3</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic HSCT</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allo HSCT with reduced-intensity conditioning</intervention_name>
    <arm_group_label>V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ALL patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALL de novo high-risk criteria

          -  Age 15-55 years (55-60 years patients will be included at the discretion of the
             medical team that will attend)

          -  No prior treatment, except Emergency leukapheresis Emergency treatment of
             hyperleukocytosis with hydroxyurea Urgent cranial irradiation (one dose) for CNS
             leukostasis Mediastinal irradiation for urgent superior vena cava syndrome

          -  General condition suitable scale (ECOG 0-2), or&gt; 2 if due to ALL

          -  Negative pregnancy test for women of childbearing age

          -  Written informed consent because, although the protocol does not include the use of
             investigational drugs, biological samples sent there for them

        Exclusion Criteria:

          -  L3 type ALL or mature phenotype B (sIg +) or cytogenetic abnormalities characteristic
             of mature B-ALL (t (8; 14), t (2, 8), t (8; 22)). For these patients is available
             BURKIMAB protocol.

          -  LAL Ph (BCR-ABL) positive. For these patients have the protocol ALL-Ph-08 (if under
             55) or LALOPh (if over 55).

          -  Lymphoid blast crisis of chronic myeloid leukemia

          -  Biphenotypic acute leukemia or bilinear according to the criteria of EGIL group

          -  Undifferentiated acute leukemias

          -  Patients with a history of coronary artery disease, valvular or hypertensive heart
             disease, contraindicating the use of anthracyclines

          -  Patients with chronic phase of activity

          -  Patients with severe chronic respiratory failure

          -  Kidney failure due to ALL

          -  Serious neurological disorder not due to the LAL

          -  History of pancreatitis

          -  Pregnancy or breastfeeding

          -  Mental or psychiatric illness preventing informed consent is given for sending samples
             or properly follow the study

          -  General condition affected, not attributable to the ALL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josep Mª Ribera, Dr</last_name>
    <phone>+ 34 93 497 88 00</phone>
    <email>jmribera@iconcologia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Mª Ribera, Dr</last_name>
      <email>jmribera@iconcologia.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://pethema.es</url>
    <description>Pethema Foundation web</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

